Fremanezumab effectiveness and tolerability in clinical routine: interim real-world-data of the observational FINESSE study

被引：0
作者：
Straube, A. [1 ]
Broessner, G. [2 ]
Gaul, C. [3 ]
Hamann, X. [4 ]
Kraya, T. [5 ,6 ]
Neeb, L. [7 ,8 ]
机构：
[1] Univ Hosp LMU Munich, Dept Neurol, Munich, Germany
[2] Innsbruck Med Univ, Dept Neurol, Innsbruck, Austria
[3] Headache Ctr Frankfurt, Frankfurt, Germany
[4] Teva GmbH, Ulm, Germany
[5] Hosp Sankt Georg Leipzig gGmbH, Dept Neurol, Headache Ctr Halle, Leipzig, Germany
[6] Univ Hosp Halle, Dept Neurol, Headache Ctr Halle, Halle, Saale, Germany
[7] Helios Global Hlth, Berlin, Germany
[8] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P040
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-world Effectiveness and Tolerability of Etrasimod in Active Ulcerative Colitis: A 26-week Observational Study
    St-Pierre, J.
    Choi, D.
    Yanofsky, R.
    Fear, E.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1540 - i1540
  • [32] Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
    Kanaan, Saad
    Hettie, Gabrielle
    Loder, Elizabeth
    Burch, Rebecca
    CEPHALALGIA, 2020, 40 (13) : 1511 - 1522
  • [33] PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine
    Ashina, Messoud
    Amin, Faisal Mohammad
    Kokturk, Pinar
    Cohen, Joshua M.
    Konings, Martijn
    Tassorelli, Cristina
    Lyras, Leonidas
    Mitsikostas, Dimos-Dimitrios
    PAIN MANAGEMENT, 2021, 11 (06) : 647 - 654
  • [34] Efficacy and tolerability of perampanel: a Chinese real-world observational study in epilepsy
    Zeng, Ya
    Wu, Xintong
    FRONTIERS IN NEUROLOGY, 2024, 14
  • [35] DESIGN OF ANIFROLUMAB STUDY OF TREATMENT EFFECTIVENESS IN THE REAL WORLD (ASTER): A MULTI-NATIONAL, OBSERVATIONAL, POST-LAUNCH STUDY TO DESCRIBE THE CLINICAL EFFECTIVENESS OF ANIFROLUMAB IN ROUTINE CLINICAL PRACTICE IN PATIENTS WITH SLE
    Mosca, M.
    Emmas, C.
    Nan, C.
    Stirnadel-Farrant, H.
    Chen, S.
    Carty, L.
    Desta, B.
    Seo, C.
    Chen, S.
    Sorrentino, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1471 - 1472
  • [36] Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE)
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Schauerte, Isabel
    Neeb, Lars
    NEUROLOGY, 2023, 100 (17)
  • [37] Real-world effectiveness of fremanezumab in patients with migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Hipp, J.
    Kraya, T.
    Schauerte, I
    Neeb, L.
    HEADACHE, 2023, 63 : 158 - 159
  • [38] Dosing, Treatment Pattern, and Safety of Finerenone Use in Routine Care: An Interim Analysis of the Prospective, Real-World, and Observational FINE-REAL Study
    Wanner, Christoph
    Wheeler, David C.
    Pantalone, Kevin M.
    Guo Lixin
    Desai, Nihar
    Correa-Rotter, Ricardo
    Navaneethan, Sankar D.
    Nicholas, Susanne B.
    Fatoba, Samuel T.
    Horvat-Broecker, Andrea
    Merz, Martin
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [39] HYPOGLOSSAL NERVE STIMULATION FOR OSA A SYSTEMATIC REVIEW OF ADVERSE EVENTS IN CLINICAL TRIALS & REAL-WORLD-DATA
    Wollny, Mathias
    Heiser, Clemens
    Ulrich, Sommer
    Christoph, Schoebel
    Braun, Marcel
    SLEEP, 2024, 47
  • [40] Interim Canadian Data from a Prospective, Observational Study of Routine Clinical Use of a Von Willebrand Factor Concentrate (Wilate®)
    Cosentino, Lidia
    James, Paula D.
    Sholzberg, Michelle
    Iorio, Alfonso
    BLOOD, 2016, 128 (22)
12345